The SPAC at­tack has just be­gun. And the Richard Bran­son deal is just the tip of the biotech ice­berg

When Richard Bran­son signed up to join the great SPAC mi­gra­tion of late 2020, you could say he had a rather broad idea of the kind of com­pa­ny he want­ed to take pub­lic. Some­thing “con­sumer fac­ing,” said the icon­ic en­tre­pre­neur in his pa­per­work.

Last week Bran­son end­ed up in the em­brace of 23andMe, sat­is­fied by the ge­net­ic test­ing the com­pa­ny made its name on along the con­sumer front and hap­py to jump in­to drug de­vel­op­ment, where the Glax­o­SmithK­line part­ner is now clear­ly fo­cused.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER